Firms

Bioverge Funds Management

Bioverge Funds Management

bioverge.comsec.gov

Bioverge Funds Management LLC is the separate wholly owned Delaware fund-management subsidiary of Bioverge, Inc., formed June 3, 2016 according to the consolidated issuer financial statements. The parent’s own legal disclosures identify it as an exempt reporting adviser registered with California; this is not a claim of SEC registered-investment-adviser status. It manages healthcare investment SPVs, deal-by-deal vehicles and diversified access funds under the shared Bioverge brand. Parent corporate crowdfunding and fund subscriptions are separate financing categories. Direct SEC Form D filings identify Neil J. Littman as Manager of Issuer’s Manager and name Bioverge Funds Management LLC. This dated unit-specific affiliation supports the named public manager core; the parent’s16-person2023 adviser/platform roster is not copied into this legal manager without an employment bridge. The genuine Bioverge brand mark is shared; a separate subsidiary-specific logo is not verified. Four primary SEC legal SPV records disclose actual sold subscription amounts: Notable VI USD325500, NutriSense II USD151093, GigaMune I USD112847 and Contraline II USD124500. Only Notable VI’s filing reports no remaining offering capacity. The others are partial sold snapshots, not verified final fund closes; first-sale and signature dates are not invented exact final-close dates. These subscriptions do not establish an exact cash ticket into a portfolio company or identify the undisclosed Modulo Bio payer vehicle.

Founded
2016
Type
Venture capital

Funds4

  • Bioverge Funds, Contraline II, LLC$124K

    Idaho2022 SPV;11investors,124500 sold/of150000,25500remaining. FirstsaleOctober26,2022/signatureNovember2, partialsold snapshot notfinalclose. ManagerBiovergeFundsManagementLLC andNeilJ.Littman primaryidentified. Amountisactualsoldsubscriptionsnapshot, not portfolio-company deliveredticket; exactfinalclosedayNULL.

  • Bioverge Funds, GigaMune I, LLC$112K

    Idaho2022 SPV;14investors,112847 sold/of150000,37153remaining. FirstsaleDecember8,2022/signatureDecember9, partialsold snapshot notfinalclose. ManagerBiovergeFundsManagementLLC andNeilJ.Littman primaryidentified. Amountisactualsoldsubscriptionsnapshot, not portfolio-company deliveredticket; exactfinalclosedayNULL.

  • Bioverge Funds, Notable VI, LLC$325K

    Idaho2023 SPV;22 investors,325500 sold/of325500,0remaining. FirstsaleFeb24,2023, signatureMarch1,2023 not independently exactcashfinalclose. ManagerBiovergeFundsManagementLLC andNeilJ.Littman primaryidentified. Amountisactualsoldsubscriptionsnapshot, not portfolio-company deliveredticket; exactfinalclosedayNULL.

  • Bioverge Funds, NutriSense II, LLC$151K

    Idaho2022 SPV;9investors,151093 sold/of160000,8907remaining. September2,2022 signature, partialsold snapshot notfinalclose. ManagerBiovergeFundsManagementLLC andNeilJ.Littman primaryidentified. Amountisactualsoldsubscriptionsnapshot, not portfolio-company deliveredticket; exactfinalclosedayNULL.

Team

Operations and support

Neil LittmanNeil LittmanManager of issuer’s manager — legal affiliation confirmed in 2022–2023 SPV filings

Co-investing

No co-investors on record yet.

Investments

No investment rounds on record yet.